Correctional Pharmacy Services Provider Security Risk Assessment Checklist

What should a correctional pharmacy security risk assessment checklist include?

A useful assessment examines how a correctional pharmacy services provider protects medication operations and the information it creates, receives, maintains, or transmits for the facility. First, establish whether the provider is a HIPAA covered entity or business associate for the services at issue. If the provider handles electronic protected health information (ePHI) on behalf of a covered entity, confirm that the applicable HIPAA Security Rule and business associate requirements are addressed in the assessment and contract.

Build the checklist around the provider’s actual services and data flows—not just its written policies. Include pharmacy systems, electronic prescriptions, dispensing and medication-administration workflows, interfaces with facility systems, remote support, cloud services, subcontractors, and any locations where data or medications are stored or handled. HHS describes HIPAA Security Rule risk analysis as an assessment of potential risks and vulnerabilities to ePHI’s confidentiality, integrity, and availability; its risk analysis guidance can help frame the review.

• Identify systems, devices, data, medication workflows, facilities, and responsible personnel within scope.
• Document reasonably anticipated threats, vulnerabilities, existing safeguards, and potential effects on patient care and facility operations.
• Assess administrative, physical, and technical safeguards, including workforce procedures and third-party vendor risk management.
• Review applicable HIPAA obligations, business associate terms, DEA requirements, and state or other contractual requirements relevant to the services.
• Record gaps, risk ratings, evidence reviewed, accountable owners, and follow-up actions.

Do not assume every pharmacy contractor has the same legal status or obligations. Determine the parties’ roles and responsibilities for each service and document that scope before evaluating controls.

How should access to pharmacy systems and controlled substances be assessed?

Check whether each person’s system access matches their job duties and is limited to what they need. Review role-based access control, unique user accounts, approval for new or changed access, prompt removal when access is no longer appropriate, periodic access reviews, and controls for privileged, remote, and emergency access. Verify that shared accounts are avoided or tightly controlled and that emergency access is traceable and reviewed.

For electronic prescriptions for controlled substances (EPCS), assess authentication, prescription review and signing, permissions to annotate or alter records, and audit trails. DEA’s EPCS guidance describes application requirements that include prescription audit trails and daily internal audits for potential security problems. Where an EPCS compromise is identified, confirm whether the applicable DEA reporting process is followed; do not treat that specific reporting requirement as a universal deadline for every type of security incident.

Assess physical security separately from system access. Review how controlled substances are received, stored, counted, transferred, returned, and disposed of; who can access storage areas; how keys or credentials are controlled; and how discrepancies are investigated and escalated. DEA states that registrants must provide effective controls and procedures to guard against theft and diversion. Consult the agency’s Practitioner’s Manual and verify the requirements that apply to the provider’s registration and operations.

• Request samples of access approvals, recent access reviews, termination records, and privileged-account monitoring.
• Trace a sample controlled-substance transaction from receipt through dispensing or other final disposition.
• Inspect how exceptions, inventory discrepancies, suspected diversion, and after-hours access are documented and investigated.

Which safeguards protect medication data and electronic prescriptions?

Evaluate safeguards that protect ePHI and medication records throughout their lifecycle. Review authentication, access controls, audit log monitoring, system integrity, endpoint and network protections, secure interfaces, patching, backups, recovery testing, and protections for data at rest and in transit. Check whether logs capture relevant events—such as access, changes, prescription activity, and administrative actions—and whether someone reviews alerts and follows up on anomalies.

Examine how electronic prescriptions are received, validated, transmitted, stored, and made available to authorized staff. For EPCS, confirm that the provider’s application and workflows meet applicable DEA requirements, and inspect the independent audit or certification report that applies to the application. DEA’s EPCS questions and answers explain that pharmacy application requirements include access limitations and an internal audit trail for prescription activity.

Encryption is an important control to assess, but avoid treating it as a universal HIPAA mandate in every circumstance. HHS identifies encryption under the Security Rule as an addressable implementation specification: the regulated entity must assess whether it is reasonable and appropriate, implement it when appropriate, and document its decision and any applicable alternative. See HHS’s explanation of encryption under the Security Rule.

• Ask how encryption, authentication, and integrity protections apply to pharmacy systems, mobile devices, backups, and interfaces.
• Review safeguards for prescription transmission and for detecting unauthorized changes or access.
• Check whether backup restoration and continuity procedures have been tested for systems needed to support medication services.
• Confirm that the provider tracks subcontractors and service providers that may access or maintain relevant data.

How can facilities evaluate provider incident response and breach reporting?

Review the provider’s written procedures for detecting, reporting, containing, investigating, and correcting security incidents. Ask who receives reports, how the provider preserves evidence, how it coordinates with the facility, and how it maintains pharmacy operations safely during an outage or cyber incident. Test the process against realistic scenarios, such as a compromised account, ransomware, a lost device, an unexplained prescription change, or suspected diversion.

Check that the contract and incident plan clearly assign responsibilities, contacts, information-sharing expectations, and response timelines. HIPAA requires business associates to report security incidents to covered entities under applicable business associate terms, and the Breach Notification Rule sets requirements for reporting a breach of unsecured PHI. HHS explains that a business associate’s notice to the covered entity must be provided without unreasonable delay and no later than 60 calendar days after discovery; that is an outer federal limit, not a recommended operational response time. Review the HHS business associate guidance and Breach Notification Rule guidance.

Assess whether the provider’s procedures distinguish routine security events from incidents that may involve reportable breaches, and whether they support timely assessment of affected information, individuals, systems, and medication services. Confirm that the facility and provider know who will make required notifications and retain documentation of decisions and actions.

What evidence should providers supply to verify security controls?

Request evidence that demonstrates controls are implemented and operating—not just policy statements. Agree on the scope, period, and secure method for sharing sensitive assessment materials. Where a document contains confidential security details or patient information, use an appropriate protected review process rather than requesting unnecessary copies.

• A current HIPAA Security Rule risk analysis and risk-management plan covering the relevant systems, services, and ePHI.
• Applicable business associate agreements and a list of subcontractors that handle or maintain relevant information.
• Policies and sample records for access approvals, access reviews, account removal, security training, incident handling, and audit log monitoring.
• Summaries of independent assessments, vulnerability testing, remediation tracking, and relevant penetration-test findings, with scope and date.
• Backup, recovery, continuity, and incident-response test results or exercise summaries.
• Evidence of applicable DEA registrations, controlled-substance security procedures, inventory reconciliation, and EPCS application audit or certification documentation.

Evaluate each item for relevance, recency, scope, exceptions, and corrective actions. A vendor report or certificate may provide useful evidence, but it does not by itself prove that the provider—or the facility—is compliant with every applicable requirement. HHS describes compliance as an ongoing process involving risk analysis, appropriate safeguards, and maintained documentation in its Security Rule guidance.

How should assessment findings and remediation deadlines be documented?

Record each finding in a risk register that links the affected system or workflow to the threat, vulnerability, existing safeguards, potential impact, and supporting evidence. Use consistent criteria to rate likelihood and impact, including consequences for ePHI, medication availability, patient safety, controlled-substance security, and facility operations.

• Assign an accountable owner and a specific corrective action to every finding.
• Set a target deadline based on risk, exposure, and operational impact; note any interim safeguards needed while remediation is underway.
• Document management approval for accepted residual risk, including the rationale and review date.
• Verify completed remediation through evidence or testing, update the risk rating, and retain the closure record.
• Escalate overdue or worsening risks and reassess when services, systems, threats, incidents, or facility operations change.

HIPAA does not prescribe one universal calendar interval for reassessing every organization’s risks. HHS explains that the frequency depends on the organization and its environment, and that risk analysis and risk management should be ongoing. Use a documented review schedule that reflects the provider’s risk and reassess after significant changes or incidents. This record—scope, evidence, findings, owners, deadlines, and verified closure—provides a practical basis for monitoring the provider’s security over time.

FAQs.

Who is responsible for completing a correctional pharmacy provider security risk assessment?

The facility should assign an accountable internal lead, often with input from security, IT, pharmacy, compliance, procurement, and clinical operations. The pharmacy provider should supply information about its controls and risks, and both parties should clarify responsibilities in their contract and any applicable business associate agreement. Outsourcing services does not eliminate each party’s own obligations under applicable law or contract.

How often should a correctional pharmacy provider’s security controls be reviewed?

Set a review schedule based on the provider’s risks, services, and changes in its environment, and review controls after significant incidents or changes. HIPAA does not set one universal frequency for a complete risk analysis; HHS says the appropriate frequency varies by organization and circumstances. A contract may establish more frequent reviews.

What documentation should a pharmacy provider provide during a security assessment?

Request relevant risk-analysis and risk-management records, security policies, access-control evidence, incident procedures, audit and testing summaries, backup and recovery test results, subcontractor information, and applicable DEA and EPCS documentation. Review materials for scope, date, exceptions, and remediation status; do not rely on a certificate or report alone as proof of comprehensive compliance.

How should security gaps identified in the assessment be prioritized?

Prioritize findings by likelihood and potential impact, considering ePHI confidentiality, integrity and availability, controlled-substance security, medication continuity, and patient safety. Assign an owner, corrective action, risk-based deadline, interim safeguards, and a method for verifying closure. Document any accepted residual risk and escalate overdue or increasing risks.